Eligibility, any sex, with JIA Associated Uveitis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Participants Reported as Complete Responders to GolimumabPrimary· last follow up, up to 5 years
Response was classified as complete, partial, or none ("non-response", NR) at each timepoint separately." Complete response (CR) constituted achieving inactive uveitis, defined as 0+ cells in the AC (grade 0). Partial response (PR) was diagnosed in patients with improved uveitis, defined as a decrease in the level of inflammation, without achieving AC grade 0 status. Primary-NR was diagnosed in patients without change in SUN score and an entry grade of 3 or higher or in patients with worsening activity, defined as either a two-grade increase in inflammation or an increase in inflammation to gr
Group
Value
95% CI
Group 1
8
Best Corrected Visual Acuity (BCVA)Secondary· up to 5 years
best corrected visual acuity
Group
Value
95% CI
Group 1
0.27
± 0.33
Number of Patients With Ocular DiscomfortSecondary· up to 5 years
Reduction in systemic steroid dose at the 12 month follow-up compared to baseline
Group
Value
95% CI
Group 1
0.19
0 – 0.52
Sponsor's own description
To asses the use of golimumab, a fully humanized anti-TNF Alpha monoclonal antibody, in juvenile idiopathic Arthritis-associated uveitis refractory to adalimumab.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
NCT05960578 — Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
· Phase 2
· active not recruiting
NCT05242484 — A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerati
· Phase 2
· active not recruiting
NCT05242471 — A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's
· Phase 2
· active not recruiting
NCT05164198 — REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST)
· Phase 4
· unknown
NCT05071664 — A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis
· Phase 2
· completed
Other Medical University of Graz trials
Trials by the same sponsor.
NCT07498244 — Collagen Fingerprinting for Stratification of Pulmonary Hypertension (PH) Patients
· recruiting
NCT07492823 — Clinical Applicability of Liquid Biopsy in Chondrosarcoma
· not yet recruiting
NCT07297615 — 3D Liver Volumetry
· NA
· not yet recruiting
NCT07588282 — The Effect of Psychoeducational Diagnosis Communication on Perception of Illness, Satisfaction, and Behavioral Intention
· NA
· recruiting
NCT07376096 — Liquid Biopsy in Germ Cell Tumors
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of Graz
Last refreshed: 5 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04200833.